Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura

Expert Review of Cardiovascular Therapy

Volumn 1, Issue 2, 2003, Pages 243-255

  Furlan, Miha ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

acquired deficiency; ADAMTS13; congenital deficiency; hemolytic; protease; purpura; Thrombotic thrombocytopenic; uremic syndrome; von Willebrand factor; von Willebrand factor cleaving

Indexed keywords

ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; METALLOPROTEINASE;

ENZYMOLOGY; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOLOGY; METABOLISM; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNITED STATES;

ADAM PROTEINS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; METALLOENDOPEPTIDASES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; UNITED STATES;

EID: 2142715413     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.1.2.243     Document Type: Review

References (97)

1. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc. NY Pathol Soc. 24, 21 – 24 (1924).
2. Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries. An undescribed disease. Arch. Intern. Med. 36, 89 – 93 (1925).
3. Kwaan HC. Clincopathologic features of thrombotic thrombocytopenic purpura. Semin. Remota]: 24, 71 – 81 (1987).
4. Torok TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States — analysis of national mortality data, 1968-1991. Am.j Remota]. 50, 84 – 90 (1995).
5. Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. B/ooc/ 16, 943 – 957 (1960).
6. Upshaw JD. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl. I Med. 298, 1350 – 1352 (1978).
7. Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. Hamolytisch-uramische Syndrome: bilaterale Nierenrindennekrosen bei akuten erworbenen hamolytischen Anarnien. Schweiz. Med. Wochenschr 85, 905 (1955).
8. Thompson CE, Damon LE, Ries CA, Linker CA. Thrombotic microangiopathies in the 80s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 80, 1890 – 1895 (1992).
9. Hellman RM, Jackson DV, Buss DH. Thrombotic thrombocytopenic purpura and hemolytic—uremic syndrome in HLA-identical siblings. Ann. Intern. Med. 93, 283 – 284 (1980).
10. Elias M, Horowitz J, Tall, Kohn D, Flatau E. Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in three siblings. Arch. Dis. Childhooc163, 644 – 646 (1988).
11. Ruggenenti P, Remuzzi G, Rossi EC. Epidemiology of the hemolytic uremic syndrome. N Engl. I Med. 324, 1065 – 1066 (1991).
12. Remuzzi G, Garella S. HUS and 1'1 P: variable expression of a single entity. I6dney Int. 32,292-308 (1987).
13. Moake JL, Chow TW. Thrombotic thrombocytopenic purpura: understanding a disease no longer rare. Am I Med. Sci 316, 105 – 119 (1998).
14. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic sindrome, and thrombotic thrombocytopenic purpura. lOdno, Int. 60, 831 – 846 (2001).
15. Furlan M, Ummle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res. Clin. Haematol. 14, 437 – 454 (2001).
16. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Corr Opin. Hematol. 8, 286 – 293 (2001).
17. Fuge R, Bird JM, Fraser A et al The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Brj Haematol 113, 58 – 64 (2001).
18. Roy V, Rizvi MA, Vesely SK, George JN. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow 7ansplant. 27,641-646 (2001).
19. Ruutu T, Hermans J, Niederwieser D et al Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). BE Haematol 118, 1112 – 1119 (2002).
20. Porta C, Caporali R, Montecucco C. Thrombotic thrombocytopenic purpura and autoimmunity: a tale of shadows and suspects. Haernatologica 84, 260 – 269 (1999).
21. McMinn J, George JN. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. j Clin. Aphetesis16,202-209 (2001).
22. Proia A, Paesano R, Torcia et al Thrombotic thrombocytopenic purpura and pregnancy: a case report and a review of the literature. Ann. Hematol. 81, 210 – 214 (2002).
23. Siddiqui FA, Lian EC-Y. Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma. I Clin. Invest. 76, 1330 – 1337 (1985).
24. Murphy WG, Moore JC. Kelton JG. Calcium-dependent cysteine protease activity in the sera of patients with thrombotic thrombocytopenic purpura. B/ooc/ 70, 1683 – 1687 (1987)
25. Ruggenenti P, Remuzzi G. The pathophysiology and management of thrombotic thrombocytopenic purpura. Eur Haematol. 56, 191 – 207 (1995).
26. Slayter H, Loscalzo J, Bockenstedt P, Handin RI. Native conformation of human von Willebrand protein. Analysis by electron microscopy and quasi-elastic light scattering. I Biol. Chem. 260, 8559 – 8563 (1985).
27. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 88, 2939 – 2950 (1996).
28. Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 46, 185 – 190 (1986).
29. Tsai HM, Nagel RL, Hatcher VB, Sussman Multimeric composition of endothelial cell-derived von Willebrand factor. Blood 73, 2074 -2076 (1989).
30. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. I Clin. Invest. 78, 1456 – 1461 (1986).
31. Moake JL, Rudy CK, Troll JH et al Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N. Engl. Med. 307, 1432 – 1435 (1982).
32. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand disease. Proc. Nat! Acad. Sc]. USA 87, 6306 – 6310 (1990).
33. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87, 4223 – 4234 (1996).
34. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. B/ooc/87, 4235 – 4244 (1996).
35. Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 83, 2171 – 2179 (1994).
36. Furlan M, Lammle B. Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura. Semin. Thromb. Hemost. 28, 167 – 172 (2002).
37. Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. B/ooc/ 91, 2839 – 2846 (1998).
38. Kinoshita S, Yoshioka A, Park Y-D et al Upshaw—Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int. J. Hematol 74, 101 – 108 (2001).
39. Tsai HM, Lian ECY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl. Med. 339, 1585 – 1594 (1998).
40. Gerritsen HE, Turecek PL, Schwarz HP, Lämmle B, Furlan M. Assay of von Willebrand factor (vWF) -cleavingprotease based on decreased collagen binding affinity of degraded vWF. A tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb. Haemost. 82, 1386 – 1389 (1999).
41. Rick ME, Moll S, Taylor MA, Krizek DM, White II GC, Aronson DL. Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb. Haemost. 88, 598 – 604 (2002).
42. Böhm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann. Hematol 81, 430 – 435 (2002).
43. Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb. Haemost. 82, 1382 – 1385 (1999).
44. Amar S, Rice L, Dong JF et al Evaluation of ADAMTS13 von Willebrand factor-cleaving metalloprotease activity using a rapid endothelial cell surface-based assay in two chronic relapsing TTP patients receiving plasma infusion. Blood 100, 123a (2002).
45. Studt JD, Böhm M, Budde U, Girma JP, Varadi K, Lämmle B. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J. Thromb. Haemost. 1, (2003) (In Press).
46. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. B/ooc/89, 3097 – 3103 (1997).
47. Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb. Haemost. 81, 8 – 13 (1999).
48. Furlan M, Robles R, Galbusera M et al von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl. Med. 339, 1578 – 1584 (1998).
49. Veyradier A, Obert B, Houllier A, Meyer D, Girma JR Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. B/ooc/ 98, 1765 – 1772 (2001).
50. Levy GG, Nichols WC, Lian EC et al Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413, 488 – 494 (2001).
51. Hunt BJ, Lämmle B, Nevard CHF, Haycock GB, Furlan M. von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb. Haemost. 85, 975 – 978 (2001).
52. Tsai HM, Chandler WL, Sarode R et al Von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coil 0157:H7-associated hemolytic uremic syndrome. Pecliatr Res. 49, 653 – 659 (2001).
53. Remuzzi G, Galbusera M, Noris M et al Von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 100,778-785 (2002).
54. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 98, 2730 – 2735 (2001).
55. Oleksowicz L, Bhagwati N, DeLeon-Fernandez M. Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies. Cancer Res. 59, 2244 – 2250 (1999).
56. Koo BH, Oh D, Chung SY et al Deficiency of von Willebrand factor-cleaving protease activity in the plasma of malignant patients. Thromb. Res. 105, 471 – 476 (2002).
57. Loof AH, van Vliet HHDM, Kappers-Klunne MC. Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura. Br. Haematol 112, 1087 – 1088 (2001).
58. Moore JC, Hayward CPM, Warkentin TE, Kelton JG. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 98, 1842 – 1846 (2001).
59. Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. j Thromb. Haemost. 1, 625 – 631 (2003).
60. Remuzzi G. Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No.” Thmmb. Haemost. 1, 632 – 634 (2003).
61. Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 100, 710 – 713 (2002).
62. Barbot J, Costa E, Guerra M et al Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. BE Haematol 113, 649 – 651 (2001).
63. Gerritsen HE, Robles R, Ummle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. B/ooc/ 98, 1654 – 1661 (2001).
64. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98, 1662 – 1666 (2001).
65. X., Zheng, D., Chung, T.K., Takayama, E.M., Majerus, J.E., Sadler, K., Fujikawa, Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura, I. Biol. Chem, (2001), 276, 41059-41063
66. Soejima K, Mimura N, Hirashima M et al A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?' Biochem. (IWO 130, 475 – 480 (2001).
67. Zheng X, Majerus EM, Sadler JE. ADAMTS13 and FIR Cur. Opin. Remota'. 9, 389 – 394 (2002)
68. Schneppenheim R, Budde U, Oyen F et al von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTR Blood 101, 1845 – 1850 (2003).
69. Kokame K, Matsumoto M, Sojima K et al Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc. Natl Acad. St”. USA 99, 11902 – 11907 (2002).
70. Plaimauer B, Zimmermann K, Völkel D et al Cloning, expression and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). B/ooc/ 100, 3626 – 3632 (2002).
71. Dong JF, Moake JL, Nolasco L et al ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100,4033-4039 (2002).
72. Dong JF, Bernardo A, Nolasco L, Padilla A, Moake J, Lopez J. ADAMTS-13 proteolysis of ultra-large von Willebrand factor multimers on the endothelial surface requires protease docking and is inhibited by thrombospondin-1. Blood 100,123a (2002).
73. Padilla A, Bernardo A, Nolasco L, Moake J, Lopez J, Dong JE A potential role for P-selectin in anchoring ultra-large von Willebrand factor multimers onto the endothelial cell surface. Blood 100, 123a-124a (2002).
74. Moake JL. Thrombotic microangiopathies. N Engl. Med. 347, 589 – 600 (2002).
75. Clark WE Rock GA, Buskard N et al Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann. Intern. Med. 131, 453 – 462 (1999).
76. Lankford KV, Grindon AJ, Lyles RII, Hillyer CD. Indications for therapeutic plasma exchange at a university hospital and a regional blood center. I Gun. Aphetesis15, 242 – 248 (2000).
77. Byrnes JJ, Moake JL, Klug P, Perlman R Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am. Remota'. 34, 169 – 174 (1990).
78. Rock G, Shumak, Sutton D, Buskard NA, Nair RC. Cryosupematant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. BE Haematol 94, 383 – 386 (1996).
79. Zeigler ZR, Shadduck RK, Gryn JF et al Cryoprecipitate poor plasma does notimprove early response in primary adultthrombotic thrombocytopenic purpura. Clin. Apheresis 16, 19 – 22 (2001).
80. Karpman D, Holmberg L, Jirgard L, Lethagen S. Increased platelet retention in familial thrombotic thrombocytopenic purpura. Kidney Int. 49, 190 – 199 (1996).
81. Lester WA, Williams MD, Allford SL, Enayat MS, Machin SJ. Successful treatment of congenital thrombotic thrombocytopenic purpura using the intermediate purity factor VIII concentrate BPL 8Y. BE I Haematol 119, 176 – 179 (2002).
82. George JN. How I treat patients with thrombotic thrombocytopenic purpura—hemolytic uremic syndrome. Blood 96, 1223 – 1229 (2000).
83. Rizvi MA, Vesely SK, George JN et al Plasma exchange complications in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 140, 896 – 901 (2000).
84. McLeod BC, Sniecinski I, Ciavarella et al Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion 39, 282 – 288 (1999).
85. Allan DS, Kovacs MJ, Clark WE Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. Haematologica 86, 844 – 850 (2001).
86. Chemnitz J, Draube A, Scheid C et al Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am. Remota]: 71, 105 – 108 (2002).
87. Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Molecules Dis. 28, 385 – 391 (2002).
88. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann. Intern. Med. 138, 105 – 108 (2003).
89. Ashida A, Nakamura H, Yoden A et al Successful treatment of a young infant who developed high-titer inhibitors against VWF-cleaving protease (ADAMTS-13): important discrimination from Upshaw—Schulman syndrome. Am.J Remota 71, 318 – 322 (2002).
90. Gaddis TG, Guthrie TH, Drew MJ, Sahud M, Howe RB, Mittelman A. Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorption. Am. J. Remota]. 55, 55 – 58 (1997).
91. Knöbl P, Haas M, Laczika K, Varadi K, Turecek PL. Immunoadsorption for the treatment of a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange: kinetics of an inhibitor of ADAMTS13. j Thromb. Haemost. 1, 187 – 189 (2003).
92. Drummond KN. Hemolytic uremic syndrome — then and now. N Engl. Merl 312, 116 – 118 (1985).
93. Warwicker P, Donne RL, Goodship JA et al Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency. Nephrol Dial. 7iamplant. 14, 1299 – 1233 (1999).
94. Noris M, Ruggenenti P, Perna A et al Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. j Am. Soc. Nephrol 10, 281 – 293 (1999).
95. Rumley A, Lowe GDO, Sweetnam PM, Yarnell JWG, Ford RP. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly heart study. Br. Haematol 105, 110 – 116 (1999).
96. Oizilbash N, Duffy S, Prentice CRM, Boothby M, Warlow C. Von Willebrand factor and risk of ischemic stroke. Neurology 49, 1552 – 1556 (1997).
97. Tsai AW, Cushman M, Rosamond WD et al Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am. Merl 113, 636 – 642 (2002).